Articles with public access mandates - Todd CreasyLearn more
Available somewhere: 9
Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction
DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ...
Cell 183 (3), 818-834. e13, 2020
Mandates: US National Institutes of Health
Natural genetic variation caused by small insertions and deletions in the human genome
RE Mills, WS Pittard, JM Mullaney, U Farooq, TH Creasy, AA Mahurkar, ...
Genome research 21 (6), 830-839, 2011
Mandates: US National Institutes of Health
Simultaneous transcriptional profiling of bacteria and their host cells
MS Humphrys, T Creasy, Y Sun, AC Shetty, MC Chibucos, EF Drabek, ...
PloS one 8 (12), e80597, 2013
Mandates: US National Institutes of Health
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
D Damotte, S Warren, J Arrondeau, P Boudou-Rouquette, ...
Journal of Translational Medicine 17, 1-10, 2019
Mandates: National Institute of Health and Medical Research, France
Impaired tumor-infiltrating T cells in patients with chronic obstructive pulmonary disease impact lung cancer response to PD-1 blockade
J Biton, H Ouakrim, A Dechartres, M Alifano, A Mansuet-Lupo, H Si, ...
American Journal of Respiratory and Critical Care Medicine 198 (7), 928-940, 2018
Mandates: National Institute of Health and Medical Research, France
Map of open and closed chromatin domains in Drosophila genome
B Milon, Y Sun, W Chang, T Creasy, A Mahurkar, A Shetty, D Nurminsky, ...
BMC genomics 15, 1-10, 2014
Mandates: US National Institutes of Health
Phenotypic, genomic, and transcriptional characterization of Streptococcus pneumoniae interacting with human pharyngeal cells
SZ Kimaro Mlacha, S Romero-Steiner, JC Dunning Hotopp, N Kumar, ...
BMC genomics 14, 1-18, 2013
Mandates: Wellcome Trust
RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma
P East, GP Kelly, D Biswas, M Marani, DC Hancock, T Creasy, ...
Nature communications 13 (1), 5632, 2022
Mandates: UK Biotechnology and Biological Sciences Research Council, Cancer Research …
Circulating immune cell and outcome analysis from the phase II study of PD-L1 blockade with durvalumab for newly diagnosed and recurrent glioblastoma
L Nayak, N Standifer, J Dietrich, JL Clarke, GP Dunn, M Lim, T Cloughesy, ...
Clinical Cancer Research 28 (12), 2567-2578, 2022
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program